TB Is Still Rife Fifty Years After The Study Which Found A Cure

Tuberculosis: story or medical failure?

In a week when the world of medicine is celebrating the 50th anniversary of the first randomised controlled trial, Chris Holme, journalist at the Herald newspaper in Glasgow, laments the irony that half a century on, the disease that this trial found the means to eradicate, is still rife.

The MRC trial, which was published in the BMJ on 30 October 1948, found Streptomycin to be an effective treatment of tuberculosis. In a stinging attack in this week's BMJ, the author writes that despite the results of this trial there has been a failure to implement treatment regimens, which has led to an international resurgence of the disease.

The author details the path of complacency that he believes has led to the epidemic we are now witnessing in the 1990s and asks: "why after an estimated one million controlled trials on every treatment under the sun, have we failed to apply the results of the initial ones on tuberculosis chemotherapy?"


Chris Holme, Herald, Glasgow, Scotland

(Contact through Jill Shepherd at BMJ press office Wednesday 28 - Friday 30 October)


Contact: Jill Shepherd
BMJ-British Medical Journal

Page: 1

Related biology news :

1. Still waters? Clear-cutting robs the deep-sea of ancient treasures
2. Salmon Syndrome M74: Cause Still A Mystery
3. Fetal Surgery For Spina Bifida Still Under Investigation At VUMC
4. Rapid Population Growth Is Still A Problem
5. Creatine Works, But Long-Term Effects Are Still Unknown
6. HIV Patients Often Experience Viral "Breakthrough," But May Still Remain Healthy, San Francisco Study Finds
7. Reduced Nutrients Still Cause Problems In The Neuse And Tar-Pamlico Rivers
8. Fifty years later, famous photo is in OSUs Pauling collection
9. Years of research, thought lead geologist to propose new supercontinent Columbia
10. Fossilized Emu Eggshells Give Clues To 65,000 Years Of Vegetation And Climate Changes In Australia
11. Earliest Modern Tree Lived 360-345 Million Years Ago

Post Your Comments:

(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. ... of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), ... Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... software solutions for biopharmaceutical R&D, today announced that it has entered into ... full-length multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable ... support testing operations in the fight against the COVID-19 pandemic in Zambia. , ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... ... the launch of its new tagline, “BUILDING FOR LIFE.” The adoption of this ... around the globe, requiring fast track capacity to provide patients with urgently needed ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign ... detection and prevention of high-burden diseases, and Centric Consulting, a business and technology ... to utilize existing data in order to identify and prioritize patients for care. ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a ... of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. ... lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine ...
Breaking Biology Technology:
Cached News: